Abstract

Bausch + Lomb Corp. will report quarterly results on July 29, 2026, Pre-MKt; this preview distills consensus forecasts, last quarter’s scorecard, key segment dynamics, and how product news and pipeline updates could shape near-term performance.

Market Forecast

Based on the latest compiled estimates, this quarter’s revenue is projected at 1.37 billion US dollars, up 8.79% year over year, with EBIT expected to reach 158.70 million US dollars, up 32.13% year over year, and adjusted EPS forecast at 0.15, up 125.78% year over year. Margin guidance for the quarter was not specified, and no consensus net margin forecast is formally indicated.

The main commercial pillars remain Devices, OTC medicines, and prescription pharmaceuticals, with Devices continuing to anchor quarterly revenue. The most promising area appears to be surgical devices and intraocular lens systems, supported by the new EyeGility Inserter launch in the United States; Devices generated 480.00 million US dollars last quarter, while company-level revenue growth is expected at 8.79% year over year this quarter.

Last Quarter Review

Last quarter, Bausch + Lomb Corp. delivered revenue of 1.24 billion US dollars (+9.41% year over year), posted a gross profit margin of 61.17%, recorded a GAAP net loss attributable to shareholders of 71.00 million US dollars with a net profit margin of -5.71%, and reported adjusted EPS of 0.08 (+214.29% year over year).

A key highlight was operating momentum, with EBIT reported at 187.00 million US dollars, up 419.44% year over year, outpacing prior expectations. On the business mix, Devices contributed 480.00 million US dollars, OTC medicines 444.00 million US dollars, and prescription pharmaceuticals 266.00 million US dollars; company revenue grew 9.41% year over year, indicating broad-based demand across the portfolio.

Current Quarter Outlook

Core Business Drivers

The quarter’s setup reflects stable demand across the company’s core commercial lines, with Devices, OTC medicines, and prescription pharmaceuticals together constituting the bulk of sales. Consensus revenue of 1.37 billion US dollars (+8.79% year over year) implies continued volume resilience and healthy price/mix across key product families. The model further embeds a notable operating expansion, with consensus EBIT at 158.70 million US dollars (+32.13% year over year) and adjusted EPS at 0.15 (+125.78% year over year).

The Devices line remains central to execution. In the prior quarter, Devices delivered 480.00 million US dollars and retained leadership in the revenue mix, which should provide operating leverage as distribution and product utilization normalize post the most recent product cycle updates. OTC medicines at 444.00 million US dollars and prescription pharmaceuticals at 266.00 million US dollars extend the base, supporting blended growth while potentially smoothing quarterly variability between surgical cycles and consumer categories.

Cost and margin cadence warrant attention. While last quarter’s gross profit margin stood at 61.17%, the reported GAAP net margin was -5.71% amid a net loss attributable to shareholders of 71.00 million US dollars. The street’s EPS and EBIT ramps for the current quarter suggest expectations for better operating efficiency and lower below-the-line drag versus the prior period, though the absence of formal gross or net margin guidance means investors will key in on conversion of EBIT to EPS and the balance between growth investments and expense control.

Highest-Potential Growth Area

Surgical devices and intraocular lens (IOL) systems appear positioned as the near-term growth catalyst. The company introduced the EyeGility Inserter in the United States as part of its enVista Aspire preloaded IOLs, with the device designed to support IOL delivery through a 2.4 mm incision and featuring a silicone soft-tipped plunger. This initiative broadens the surgical toolkit and is aimed at improving operating room efficiency and consistency, which are important for surgeon adoption and procedural throughput.

The launch cadence is a meaningful driver for utilization and mix, particularly as facilities and surgeons integrate the updated inserter into their workflows. Given Devices’ 480.00 million US dollars contribution last quarter and the market’s expectation for company-level revenue growth of 8.79% year over year this quarter, incremental adoption from new toolkits can lift volumes, support premium product mix, and anchor EBIT progression. Execution focus will be on availability, surgeon training, and evidence of repeat ordering that signals durable uptake beyond initial trials.

Beyond surgical tools, product news in the pipeline can also influence expectations around the prescription portfolio over the medium term. While a recent phase 2 study for a glaucoma neuroprotective candidate did not meet its primary endpoint and is not progressing as a topical eye drop in that indication, management’s portfolio actions—highlighted by an announced 1.75 billion US dollars deal to acquire a Novartis dry-eye asset—underscore a continuing strategy to fortify the therapeutic franchise. The net effect for this quarter is more about sentiment and future optionality than immediate P&L, but the combination of commercial launches and pipeline or business development updates helps frame the multiquarter runway.

Key Stock Price Swing Factors This Quarter

Earnings translation will likely hinge on how much of the EBIT uplift converts to adjusted EPS relative to last quarter’s cadence. With consensus calling for 158.70 million US dollars of EBIT and 0.15 in adjusted EPS, investors will parse the contribution of operating leverage versus non-operating items to understand sustainability into the back half. Delivery against the revenue mix—especially Devices and associated surgical tools—may serve as a visible signal of the quarter’s trajectory.

Product execution around the EyeGility Inserter is a tangible signal for the Devices franchise, where reliable supply, surgeon feedback, and early reorder rates can shape both revenue quality and margin trajectory. A positive reception would support the idea that surgical innovation can continue to pull through higher-value lens systems and accessories, strengthening price/mix and reinforcing EBIT. Conversely, any onboarding frictions would likely show up as a timing issue more than a structural demand concern, but they could still influence near-term trading into the print.

Pipeline and portfolio headlines can also swing sentiment. The non-advancement of the glaucoma neuroprotective program as a topical eye drop removes one potential medium-term driver, but the announced acquisition of a Novartis dry-eye asset provides a counterweight by potentially expanding the therapeutic portfolio. Investors will watch for updates on regulatory milestones, integration timelines, and any color regarding commercialization pathways, given that these factors influence the revenue growth profile beyond this quarter, even if limited impact flows through the immediate results.

Analyst Opinions

The recent rating balance tracked since January 1, 2026 skews bullish: among the calls captured, the share of bullish opinions versus bearish is 100% to 0% when excluding neutral stances. Analysts spotlight consistent execution and product catalysts as underpinnings for their views, aligning with the consensus trajectory for revenue (+8.79% year over year), EBIT (+32.13% year over year), and adjusted EPS (+125.78% year over year) this quarter.

Citi’s Joanne Wuensch reiterated a Buy rating with a 21.00 US dollars price target, pointing to a constructive outlook into the upcoming results window and an emphasis on delivery against revenue and earnings estimates. RBC Capital’s Douglas Miehm maintained a Buy and a 21.00 US dollars target, reflecting confidence in ongoing commercial performance and the benefit of surgical product momentum to support EBIT and EPS carry-through. Morgan Stanley’s Patrick Wood also maintained a Buy with a 21.00 US dollars target, consistent with the view that a combination of steady core demand and pipeline or portfolio actions can support the multiquarter growth thesis.

Taken together, the majority view expects Bausch + Lomb Corp. to post solid year-over-year growth with improving operating conversion in the current quarter. The bullish stance emphasizes timely execution in Devices—particularly visibility into surgeon adoption of newer insertion systems—while monitoring updates around therapeutic portfolio moves that could bolster future revenue streams. This aligns with the market’s current modeling of a 1.37 billion US dollars revenue print, 158.70 million US dollars in EBIT, and 0.15 adjusted EPS, framing a path where commercial performance and selective innovation drive both the quarter and the outlook into subsequent periods.